Nola M. Hylton, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Nola M. Hylton, PhD

Professor in Residence, Department of Radiology, UCSF; and Director, Magnetic Resonance Science Center

Nola.Hylton@radiology.ucsf.edu

Phone: (415) 476-8856, 476-9023 (voice)
Box 1290, UCSF
San Francisco, CA 94143-1290

View on UCSF Profiles

Cancer Center Membership

Program Member » Breast Oncology

Education

Massachusetts Institute of Technology (M.I.T.), B.S., 1979, Chemical Engineering
Stanford University, Ph.D., 1985, Applied Physics

Professional Experience

  • 6/76-8/76
    Technical Associate, Bell Telephone Laboratories, Murray Hill, N.J.
  • 6/77-8/77
    Research Assistant, Bell Telephone Laboratories, Murray Hill, N.J.
  • 6/78-8/78
    Research Assistant, Bell Telephone Laboratories, Murray Hill, N.J.
  • 9/79-12/82
    Research Assistant, E. L. Ginzton Laboratory, Stanford University, Stanford,California
  • 1/83-12/84
    Research Assistant, Radiologic Imaging Laboratory, Department of Radiology, University of California, San Francisco
  • 1/85-7/92
    Assistant Professor, Radiologic Imaging Laboratory, Department of Radiology, University of California, San Francisco
  • 7/90-9/97
    Faculty Member, Graduate Group in Biophysics, University of California, San Francisco
  • 7/92-6/95
    Assistant Professor, Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco
  • 7/95-6/02
    Associate Adjunct Professor, Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco
  • 9/97-present
    Faculty Member, Bioengineering Graduate Group, University of California, San Francisco and University of California, Berkeley
  • 1/98-present
    Faculty Member, Breast Oncology Program, UCSF Cancer Center
  • 7/02-present
    Professor in Residence, Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco
  • 2/04-present
    Director, Magnetic Resonance Science Center, Dept. of Radiology, UCSF

Selected Publications

  1. Bertrand KA, Baer HJ, Orav EJ, Klifa C, Shepherd JA, Van Horn L, Snetselaar L, Stevens VJ, Hylton NM, Dorgan JF. Body fatness during childhood and adolescence and breast density in young women: a prospective analysis. Breast Cancer Res. 2015; 17(1):95.
    View on PubMed
  2. Jung S, Egleston BL, Chandler DW, Van Horn L, Hylton NM, Klifa CC, Lasser NL, LeBlanc ES, Paris K, Shepherd JA, Snetselaar LG, Stanczyk FZ, Stevens VJ, Dorgan JF. Adolescent endogenous sex hormones and breast density in early adulthood. Breast Cancer Res. 2015 Jun 4; 17(1):77.
    View on PubMed
  3. Galbán CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD. Multi-Site Clinical Evaluation of DW-MRI as a Treatment Response Metric for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. PLoS One. 2015; 10(3):e0122151.
    View on PubMed
  4. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias A, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde LA, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder S, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin E, Rugo HS, Symmans WF, Tripathy D, van 't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Feb 24.
    View on PubMed
  5. Hollowell L, Price E, Arasu V, Wisner D, Hylton N, Joe B. Lesion morphology on breast MRI affects targeted ultrasound correlation rate. Eur Radiol. 2015 May; 25(5):1279-84.
    View on PubMed
  6. Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1464-83.
    View on PubMed
  7. Aliu SO, Jones EF, Azziz A, Kornak J, Wilmes LJ, Newitt DC, Suzuki SA, Klifa C, Gibbs J, Proctor EC, Joe BN, Hylton NM. Repeatability of quantitative MRI measurements in normal breast tissue. Transl Oncol. 2014 Feb; 7(1):130-7.
    View on PubMed
  8. Chenevert TL, Malyarenko DI, Newitt D, Li X, Jayatilake M, Tudorica A, Fedorov A, Kikinis R, Liu TT, Muzi M, Oborski MJ, Laymon CM, Li X, Thomas Y, Jayashree KC, Mountz JM, Kinahan PE, Rubin DL, Fennessy F, Huang W, Hylton N, Ross BD. Errors in Quantitative Image Analysis due to Platform-Dependent Image Scaling. Transl Oncol. 2014 Feb; 7(1):65-71.
    View on PubMed
  9. Boes JL, Hoff BA, Hylton N, Pickles MD, Turnbull LW, Schott AF, Rehemtulla A, Chamberlain R, Lemasson B, Chenevert TL, Galb N CJ, Meyer CR, Ross BD. Image registration for quantitative parametric response mapping of cancer treatment response. Transl Oncol. 2014 Feb; 7(1):101-10.
    View on PubMed
  10. Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM. Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform. Transl Oncol. 2014 Feb; 7(1):94-100.
    View on PubMed
  11. Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. J Magn Reson Imaging. 2014 Aug; 40(2):476-82.
    View on PubMed
  12. Wang J, Azziz A, Fan B, Malkov S, Klifa C, Newitt D, Yitta S, Hylton N, Kerlikowske K, Shepherd JA. Agreement of mammographic measures of volumetric breast density to MRI. PLoS One. 2013; 8(12):e81653.
    View on PubMed
  13. Wisner DJ, Rogers N, Deshpande VS, Newitt DN, Laub GA, Porter DA, Kornak J, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3T. J Magn Reson Imaging. 2014 Sep; 40(3):674-81.
    View on PubMed
  14. Wisner DJ, Hwang ES, Chang CB, Tso HH, Joe BN, Lessing JN, Lu Y, Hylton NM. Features of occult invasion in biopsy-proven DCIS at breast MRI. Breast J. 2013 Nov-Dec; 19(6):650-8.
    View on PubMed
  15. McLaughlin RL, Newitt DC, Wilmes LJ, Jones EF, Wisner DJ, Kornak J, Proctor E, Joe BN, Hylton NM. High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: a pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging. J Magn Reson Imaging. 2014 May; 39(5):1308-13.
    View on PubMed
  16. Dorgan JF, Klifa C, Deshmukh S, Egleston BL, Shepherd JA, Kwiterovich PO, Van Horn L, Snetselaar LG, Stevens VJ, Robson AM, Lasser NL, Hylton NM. Menstrual and reproductive characteristics and breast density in young women. Cancer Causes Control. 2013 Nov; 24(11):1973-83.
    View on PubMed
  17. Ojeda-Fournier H, de Guzman J, Hylton N. Breast magnetic resonance imaging for monitoring response to therapy. Magn Reson Imaging Clin N Am. 2013 Aug; 21(3):533-46.
    View on PubMed
  18. Bolouri MS, Elias SG, Wisner DJ, Behr SC, Hawkins RA, Suzuki SA, Banfield KS, Joe BN, Hylton NM. Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging. Radiology. 2013 Nov; 269(2):354-61.
    View on PubMed
  19. Mukhtar RA, Yau C, Rosen M, Tandon VJ. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12):3823-30.
    View on PubMed
  20. Yitta S, Joe BN, Wisner DJ, Price ER, Hylton NM. Recognizing artifacts and optimizing breast MRI at 1.5 and 3 T. AJR Am J Roentgenol. 2013 Jun; 200(6):W673-82.
    View on PubMed

Go to UCSF Profiles, powered by CTSI